JGJorge Luis Gamboa

Jorge Luis Gamboa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jorge Luis Gamboa has a total of 384 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Skeletal muscle adaptation to home-based exercise in chronic kidney disease

    by Sarah E. Brashear, Anas Mohamed Sulthan, Denise Chan, Vishal Rao, Gwenaelle Begue, Armin Ahmadi, Tae Youn Kim, Jennifer E. Norman, Usman Rehman, Thomas Jue, et al.

    This study investigates the impact of a home-based, video-monitored 12-wk exercise program, consisting of both endurance and resistance exercise, on skeletal muscle structural remodeling in persons with chronic kidney disease. We found this program increased capillaries and decreased fibroadipogenic progenitors after exercise.

  • Open Access

    Cellular senescence in skeletal muscle: myogenic and nonmyogenic cell populations, mechanisms, and therapeutic opportunities

    by Konstantinos Papanikolaou, Angad Yadav, Robert T. Mankowski, Matthew S. Alexander, Jorge L. Gamboa, Anna E. Thalacker-Mercer, Cory M. Dungan, Davis A. Englund

    Skeletal muscle plays a central role in systemic metabolism, physical function, and overall health. Aging and disease diminish the ability of myogenic and nonmyogenic skeletal muscle cells to coordinate adaptation and repair, but the mechanisms underlying this decline are not fully understood. Growing evidence implicates cellular senescence, a stress response marked by irreversible cell cycle arrest and proinflammatory signaling, as a key contributor to muscle pathology. In this review, we synthesize current insights into the molecular mechanisms that govern cellular senescence in skeletal muscle, its effects on myogenic and nonmyogenic cell populations, and recent technologies that have clarified key aspects of senescence biology. We further explore emerging therapeutic strategies aimed at targeting senescent cells and discuss key knowledge gaps that must be addressed to advance our understanding of senescent myogenic and nonmyogenic cells in skeletal muscle.


  • Systemic Phosphate Elevations Induce Fibroblast Growth Factor 23 Production in Skeletal Muscle to Reduce Renal Phosphate Reabsorption in Mice

    by Kylie Heitman, Qing Li, Abul Fajol, Matthew Denniff, Dungeng Peng, S. Madison Thomas, Brian Czaya, Christopher Yanucil, David Westbrook, Syed Wasiuddin, et al.

    Key Points: Our study identified skeletal muscle as a novel source of fibroblast growth factor 23 (FGF23) in scenarios of hyperphosphatemia, including high dietary phosphate intake and CKD. Skeletal muscle–derived FGF23 had endocrine actions lowering serum phosphate levels, which may protect from hyperphosphatemia-induced tissue damages. Skeletal muscle–derived FGF23 might also have paracrine effects counteracting atrophy. Background: Fibroblast growth factor 23 (FGF23) is a hormone that reduces the renal reabsorption of phosphate in response to systemic phosphate elevations. In CKD, serum levels of phosphate and FGF23 reach levels that can harm various tissues. While the bone acts as the main production site for FGF23, bone-specific gene deletion studies in mice suggest the existence of other FGF23 sources. Here, we determine if skeletal muscle produces FGF23 in response to phosphate elevations. Methods: We studied four mouse models with phosphate elevations, two with CKD (global Col4a3 deletion and adenine-rich diet) and two without CKD (genetic klotho deficiency and high-phosphate diet). Furthermore, we generated a new mouse line with skeletal muscle–specific Fgf23 deletion (KO), which received an adenine-rich or a high-phosphate diet. We measured skeletal muscle FGF23 by quantitative real-time PCR, ELISA, and immunohistochemistry, as well as serum levels of phosphate, FGF23, and parathyroid hormone (PTH). We determined FGF23 mRNA levels in muscle biopsies from patients with CKD, and we studied the effects of phosphate and PTH elevations on FGF23 expression in cultured myotubes isolated from mice and patients with CKD. Finally, we studied the effects of acute phosphate loading on urine phosphate levels in Fgf23 KO mice. Results: All four mouse models with phosphate and PTH elevations showed FGF23 expression in skeletal muscle tissue on mRNA and protein level. Phosphate, but not PTH, induced FGF23 expression in cultured myotubes. Furthermore, patients with CKD with higher serum phosphate levels expressed more FGF23 in skeletal muscle. Fgf23 KO mice had elevated serum phosphate levels when administered a high-phosphate diet and decreased urine phosphate levels after acute phosphate loading. Conclusions: Phosphate elevations induced FGF23 expression in skeletal muscle, independent of the absence or presence of CKD. Skeletal muscle–derived FGF23 reduced renal phosphate reabsorption.


  • Soft tissue accumulations of phosphate are not always associated with serum phosphate or with calcifications in mouse models of hyperphosphatemia

    by Abul Fajol, Kylie Heitman, S. Madison Thomas, Qing Li, Tanecia Mitchell, Jorge Gamboa, Abolfazl Zarjou, Orlando M. Gutierrez, Christian Faul

    High serum levels of phosphate (hyperphosphatemia) can target vascular smooth muscle cells (VSMC) and induce calcium‐phosphate precipitations and vascular calcification, thereby contributing to high cardiovascular mortality rates in chronic kidney disease (CKD). Calcifications within soft tissues beyond the vasculature are not well described, and the involvement of cell types other than VSMCs is not clear. Here, we studied extravascular calcifications in various soft tissues from mouse models with hyperphosphatemia. We found that klotho‐deficient ( kl/kl ) mice without CKD not only developed calcifications in the aorta, but also in the kidney and stomach, which was accompanied by significant elevations in tissue content of phosphate. Administration of a magnesium‐rich diet, which blocks the formation of calcium‐phosphate crystals, prevented calcifications in these tissues. Liver, heart, skeletal muscle, spleen, brain and skin showed no signs of calcifications. Similarly, CKD mice with global deletion of Col4a3 ( Col4a3 −/− ) showed significant increases in phosphate content and calcifications in aorta, kidney and stomach, but only when administered a high phosphate diet, which was not accompanied by further elevations in serum phosphate levels. In Col4a3 −/− mice on normal chow, we could only detect an increase in liver phosphate content that occurred in the absence of hepatic calcifications. Our findings indicate that soft tissue calcifications are not always associated with increases in serum phosphate concentrations. Furthermore, in some tissues, the accumulation of phosphate occurs independently of serum phosphate elevations and is not necessarily accompanied by calcifications. Overall, our findings indicate that soft tissues differ in their response to hyperphosphatemia. image Key points: It is known that high serum phosphate levels (hyperphosphatemia) cause vascular calcifications, which are accompanied by increases in tissue phosphate content. Here, we show in mouse models of hyperphosphatemia that calcifications also occur in soft tissue areas outside of the vasculature (extravascular calcification). We also found that in some soft tissues the accumulation of phosphate is not accompanied by calcifications and occurs independently of serum phosphate elevations. Our findings indicate that soft tissues differ in their response to hyperphosphatemia. Because tissue elevations of phosphate drive the calcification process, CKD studies to determine causalities between hyperphosphatemia, tissue injuries and mortality should not be restricted to measuring phosphate levels in the circulation. Our finding that the administration of a magnesium‐rich diet protects hyperphosphatemic mice from phosphate accumulations and calcifications in various soft tissues supports ongoing clinical trials that aim to determine the beneficial effects of magnesium elevations in patients with CKD.


  • Open Access

    Intermuscular adipose tissue and muscle function in patients on maintenance hemodialysis

    by R. Gulsah Dilaver, Mert Demirci, Rachelle Crescenzi, Michael Pridmore, Lale A. Ertuglu, Andrew Guide, Robert Greevy, Baback Roshanravan, T. Alp Ikizler, Jorge L. Gamboa

    Sarcopenia is common in advanced chronic kidney disease (CKD), contributing to poor outcomes. Intermuscular adipose tissue (IMAT) may worsen muscle function through metabolic and inflammatory pathways. We conducted a cross‐sectional study comparing maintenance hemodialysis (MHD) patients and controls to assess IMAT and its associations. IMAT was measured via calf muscle MRI, and body composition (BMI, fat mass index), metabolic markers (hs‐CRP, TNF‐α, IL‐6, insulin resistance), and circulating cell‐free mitochondrial DNA (ccf‐mtDNA) were assessed. Muscle function was evaluated with handgrip strength. IMAT differences between groups were tested using inverse propensity weighting. We analyzed 25 MHD patients and 23 controls. Median age was 53 years, BMI 30.4 kg/m2, 83% were male, and 56% were African American. Baseline characteristics were similar between groups, except for race. MHD patients had higher IMAT (p < 0.01) and elevated TNF‐α, IL‐6, and hs‐CRP (p < 0.01). IMAT was positively correlated with IL‐6 in MHD patients and with TNF‐α in controls. Handgrip strength was inversely correlated with IMAT in the full cohort (p < 0.01). Our findings highlight the role of IMAT in inflammation and functional decline in CKD, suggesting its potential as a therapeutic target.


  • Intermuscular Adipose Tissue in CKD

    by Mert Demirci, R. Gulsah Dilaver, Baback Roshanravan, T. Alp Ikizler, Jorge L. Gamboa

    Patients with CKD often experience loss of muscle mass, altered muscle function, and low physical functionality, all of which contribute to increased mortality and morbidity. Mitochondrial dysfunction emerges early in the progression of CKD and may play a central role in physical dysfunction. Factors such as uremia, systemic inflammation, oxidative stress, and inappropriate activation of the renin-angiotensin-aldosterone system may play a role on mitochondrial dysfunction. On the other hand, the accumulation of ectopic adipose tissue in skeletal muscle, also known as intermuscular adipose tissue (IMAT), is a newly recognized factor in muscle function and physical performance. IMAT is a marker of muscle quality, adversely affecting local muscle function, and is associated with insulin resistance and systemic inflammation, conditions commonly observed in CKD. Nevertheless, the exact composition of IMAT and its relationship with mitochondria and muscle energetics in CKD is not fully understood. Evaluating the relationship between IMAT accumulation and mitochondrial dysfunction in CKD may unveil potential interventions to improve physical function and the quality of life of patients with CKD.


  • Open Access

    A Pilot Trial of Nicotinamide Riboside and Coenzyme Q10 on Inflammation and Oxidative Stress in CKD

    by Armin Ahmadi, Ana P. Valencia, Gwénaëlle Begue, Jennifer E. Norman, Sili Fan, Blythe P. Durbin-Johnson, Bradley N. Jenner, Matthew D. Campbell, Gustavo Reyes, Pankaj Kapahi, et al.

    Key Points: Nicotinamide riboside and coenzyme Q10 supplementation showed distinct beneficial effects on whole-blood transcriptome, inflammatory cytokines, and oxidative stress. Nicotinamide riboside treatment altered the expression of genes associated with metabolism and immune response coinciding with a decrease in markers of oxidative stress. Coenzyme Q10 supplementation altered genes associated with lipid metabolism coinciding with reductions in markers of oxidative stress and inflammatory cytokines. Background: Mitochondria-driven oxidative/redox stress and inflammation play a major role in CKD pathophysiology. Compounds targeting mitochondrial metabolism may improve mitochondrial function, inflammation, and redox stress; however, there is limited evidence of their efficacy in CKD. Methods: We conducted a pilot, randomized, double-blind, placebo-controlled crossover trial comparing the effects of 1200 mg/d of coenzyme Q10 (CoQ10) or 1000 mg/d of nicotinamide riboside (NR) supplementation with placebo in 25 patients with moderate-to-severe CKD (eGFR 2). We assessed changes in blood transcriptome using 3′-Tag-Seq gene expression profiling and changes in prespecified secondary outcomes of inflammatory and oxidative stress biomarkers. For a subsample of participants (n=14), we assessed lymphocyte and monocyte bioenergetics using an extracellular flux analyzer. Results: The (mean±SD) age, eGFR, and body mass index of the participants were 61±11 years, 37±9 ml/min per 1.73 m2, and 28±5 kg/m2, respectively. Of the participants, 16% had diabetes and 40% were female. Compared with placebo, NR-mediated transcriptomic changes were enriched in gene ontology terms associated with carbohydrate/lipid metabolism and immune signaling, whereas CoQ10 changes were enriched in immune/stress response and lipid metabolism gene ontology terms. NR increased plasma IL-2 (estimated difference, 0.32; 95% confidence interval [CI], 0.14 to 0.49 pg/ml), and CoQ10 decreased both IL-13 (estimated difference, −0.12; 95% CI, −0.24 to −0.01 pg/ml) and C-reactive protein (estimated difference, −0.11; 95% CI, −0.22 to 0.00 mg/dl) compared with placebo. Both NR and CoQ10 reduced five-series F2-isoprostanes (estimated difference, −0.16 and −0.11 pg/ml, respectively; P < 0.05 for both). NR, but not CoQ10, increased the Bioenergetic Health Index (estimated difference, 0.29; 95% CI, 0.06 to 0.53) and spare respiratory capacity (estimated difference, 3.52; 95% CI, 0.04 to 7 pmol/min per 10,000 cells) in monocytes. Conclusions: Six weeks of NR and CoQ10 improved markers of oxidative stress, inflammation, and cell bioenergetics in patients with moderate-to-severe CKD. Clinical Trial registry name and registration number: NCT03579693.


  • Open Access

    An ergometer dataset to measure muscle bioenergetics with magnetic resonance techniques

    by Usman Rehman, Gwenaelle Begue, Armin Ahmadi, Paolo Taboga, Jorge Gamboa, Baback Roshanravan, Thomas Jue


  • Open Access

    Impaired Incretin Homeostasis in Nondiabetic Moderate-to-Severe CKD

    by Armin Ahmadi, Jorge Gamboa, Jennifer E. Norman, Bamba Enkhmaa, Madelynn Tucker, Brian J. Bennett, Leila R. Zelnick, Sili Fan, Lars F. Berglund, Talat Alp Ikizler, et al.

    Key Points: Total incretin levels and incretin response during oral glucose tolerance testing were significantly higher among patients with moderate-to-severe nondiabetic patients with CKD compared with healthy people. Unlike in healthy individuals, increased incretin response was not correlated with insulin response and coincided with persistently greater glucagon levels to oral glucose tolerance testing in CKD. Disruption in the incretin system and glucagon dynamics may contribute to metabolic complications in moderate-to-severe CKD. Background: Incretins are regulators of insulin secretion and glucose homeostasis metabolized by dipeptidyl peptidase-4 (DPP-4). CKD may modify incretin release, metabolism, or response. Methods: We performed 2-hour oral glucose tolerance testing in 59 people with nondiabetic CKD (eGFR 2 ) and 39 matched controls. We measured total area under the curve and incremental area under the curve (iAUC) of plasma total glucagon-like peptide-1 (GLP-1) and total glucose-dependent insulinotropic polypeptide (GIP). Fasting DPP-4 levels and activity were measured. Linear regression was used to adjust for demographic, body composition, and lifestyle factors. Results: Mean (SD) eGFR was 38±13 and 89±17 ml/min per 1.73 m 2 in patients with CKD and controls, respectively. GLP-1 total area under the curve and GIP iAUC were higher in patients with CKD than controls with a mean of 1531±1452 versus 1364±1484 pM×min and 62,370±33,453 versus 42,365±25,061 pg×min/ml, respectively. After adjustment, CKD was associated with 15,271 pM×min/ml greater GIP iAUC (95% confidence intervals [CIs], 387 to 30,154) compared with controls. Adjustment for covariates attenuated associations of CKD with higher GLP-1 iAUC (adjusted difference, 122; 95% CI, −619 to 864). Plasma glucagon levels were higher at 30 minutes (mean difference, 1.6; 95% CI, 0.3 to 2.8 mg/dl) and 120 minutes (mean difference, 0.84; 95% CI, 0.2 to 1.5 mg/dl) in patients with CKD compared with controls. There were no differences in insulin levels or plasma DPP-4 activity or levels between groups. Conclusions: Overall, incretin response to oral glucose is preserved or augmented in moderate-to-severe CKD, without apparent differences in circulating DPP-4 concentration or activity. However, neither insulin secretion nor glucagon suppression is enhanced.


  • Open Access

    Intermuscular adipose tissue accumulation is associated with higher tissue sodium in healthy individuals

    by Lale A. Ertuglu, Melis Sahinoz, Aseel Alsouqi, Serpil Muge Deger, Andrew Guide, Mindy Pike, Cassianne Robinson‐Cohen, Elvis Akwo, Michael Pridmore, Rachelle Crescenzi, et al.

    Background and Aims: High tissue sodium accumulation and intermuscular adipose tissue (IMAT) are associated with aging, type 2 diabetes, and chronic kidney disease. In this study, we aim to investigate whether high lower‐extremity tissue sodium accumulation relates to IMAT quantity and whether systemic inflammatory mediators and adipocytokines contribute to such association.Methods: Tissue sodium content and IMAT accumulation (percentage of IMAT area to muscle area) were measured in 83 healthy individuals using sodium imaging (23Na‐MRI) and proton (1H‐MRI) imaging of the calf. Insulin sensitivity was assessed by glucose disposal rate (GDR) measured with the hyperinsulinemic‐euglycemic clamp.Results: Median (interquartile range) muscle and skin sodium contents were 16.6 (14.9, 19.0) and 12.6 (10.9, 16.7) mmol/L, respectively. Median IMAT was 3.69 (2.80, 5.37) %. In models adjusted for age, sex, BMI, GDR, adiponectin, and high‐sensitivity C‐reactive protein, increasing tissue sodium content was significantly associated with higher IMAT quantity (p = 0.018 and 0.032 for muscle and skin tissue sodium, respectively). In subgroup analysis stratified by sex, skin sodium was significantly associated with IMAT only among men. In interaction analysis, the association between skin sodium and IMAT was greater with increasing levels of high‐sensitivity C‐reactive protein and interleukin‐6 (p for interaction = 0.022 and 0.006, respectively).Conclusions: Leg muscle and skin sodium are associated with IMAT quantity among healthy individuals. The relationship between skin sodium and IMAT may be mediated by systemic inflammation.